Singapore markets close in 1 hour 56 minutes

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.7700+0.0600 (+2.21%)
At close: 04:00PM EDT
2.7700 0.00 (0.00%)
After hours: 04:02PM EDT

Lyell Immunopharma, Inc.

201 Haskins Way
South San Francisco, CA 94080
United States
650 695 0677
https://lyell.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees224

Key executives

NameTitlePayExercisedYear born
Dr. Richard D. Klausner M.D.Founder & Executive Chairman80kN/A1952
Dr. Lynn Seely M.D., Ph.D.President, CEO & Director962.23kN/A1959
Mr. Charles W. NewtonChief Financial Officer744.74kN/A1971
Mr. Stephen J. HillChief Operating Officer775.97kN/A1970
Dr. Gary Lee Ph.D.Chief Scientific Officer889.68kN/A1977
Mr. Matthew Lang J.D.Chief Business Officer, Chief Legal Officer & Corporate Secretary596.25kN/A1976
Prof. Stanley R. Riddell M.D.Founder & Scientific AdvisorN/AN/AN/A
Dr. Crystal L. Mackall M.D.Founder & Scientific AdvisorN/AN/A1961
Nellie DilleryDirector of AccountingN/AN/AN/A
Ms. Ellen RoseSenior Vice President of Communications & Investor RelationsN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Corporate governance

Lyell Immunopharma, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 3; Board: 7; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.